Progress of vericiguat in treatment of heart failure
10.3760/cma.j.cn114798-20230315-00217
- VernacularTitle:维利西呱治疗心力衰竭的研究进展
- Author:
Lei ZHANG
1
;
Lingling QIAN
;
Ruxing WANG
Author Information
1. 南京医科大学附属无锡人民医院心内科，无锡 214023
- Keywords:
Heart failure;
Soluble guanylate cyclase;
Vericiguat
- From:
Chinese Journal of General Practitioners
2023;22(11):1210-1214
- CountryChina
- Language:Chinese
-
Abstract:
Heart failure is the end stage of many cardiovascular diseases and has a high morbidity and mortality. With the improvements of treatment, the survival of heart failure patients has been prolonged, but still some patients are repeatedly hospitalized due to deterioration of conditions and have poor prognosis, thus seeking new therapeutic options is required. Vericiguat is a novel oral soluble guanylate cyclase stimulator that enhances the cyclic guanosine monophosphate pathway by directly stimulating soluble guanylate cyclase through a nitric oxide-independent binding site and sensitizes soluble guanylate cyclase to endogenous nitric oxide by stabilizing the binding site. Large clinical trials have shown that vericiguat reduces the risk of readmission for heart failure, improves prognosis, and has been approved for use in patients with heart failure with chronically reduced ejection fraction. This article reviews the mechanism and related clinical studies of vericiguat in the treatment of heart failure.
